Thursday, February 04, 2016 5:55:38 AM
Tecfidera TRX 8,509 -1.2% NRX 2,213 -2.0%
Copaxone TRX 9,154 -4.2% NRX 2,126 -7.7%
Glatopa TRX 710 -3.8% NRX 213 -9.7%
From these numbers I'd say we're stuck in the mud. Roughly speaking, it looks like Teva probably is approaching the 80% mark of converting patients to their 3X dosing schedule. It looks like Teva and Sandoz are just about splitting the Daily users 50-50.
Momenta needs a break.
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM